Articles tagged with Metastasis
A recent study published in Nature Communications found that healthy developing neurons promote metastatic behaviour in neuroblastoma cells. This discovery highlights the importance of understanding the unique developmental environment within which cancers of embryonic origin form.
Researchers found phosphatidylinositol bisphosphate (PIP2) essential for epithelial cell-cell adhesion and maintaining cellular identity. PIP2 regulates epithelial properties by recruiting Par3 to the plasma membrane, facilitating the formation of adherens junctions and preventing epithelial-mesenchymal transformation.
A team of researchers used a CRISPR-based approach to study the evolution of lung cancer cells, tracking their history from the first activation of cancer-causing mutations. The study revealed significant diversity between subpopulations of cells within the same tumor, with certain groups becoming more fit and aggressive over time.
Researchers created patient-derived models of brain metastases that recapitulate human disseminated disease, reflecting clinical manifestations and biological characteristics. These models can be used to test therapeutic value of different treatments and explore new approaches tailored to each patient.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Mount Sinai have discovered a previously unknown mechanism by which not-yet-malignant breast cancer cells can travel to other organs and 'turn on' to become metastatic. The study identified potential diagnostic biomarkers, including the transcription factor NR2F1, that could help predict relapse.
Researchers from IRB Barcelona and Merus have discovered MCLA-158, a bi-specific antibody targeting cancer stem cells. The treatment prevents metastasis and slows primary tumor growth in experimental models of cancer.
Research from Weill Cornell Medicine found that less prostate cancer screening has reduced overdiagnosis, but increased incidence of high-grade and metastatic disease. The study analyzed over 438,000 men with newly diagnosed prostate cancer between 2010 and 2018.
Researchers discovered that sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances cancer cell invasion. ST6Gal-I, an enzyme that adds sialic acid to EGFR, plays a key role in tumor progression and metastasis.
A team of biologists identified a protein involved in the spread of breast cancer to bones. The discovery confirms the importance of cellular plasticity during the metastatic process and could lead to new treatments. ZEB1, a protein that increases cell plasticity, was found to direct cells with metastatic characteristics to bones.
Researchers at the University of Oklahoma are testing a novel therapy that combines local laser ablation and immunostimulants to treat metastatic pancreatic cancer. The treatment aims to stimulate the immune system to fight cancer cells, with promising preliminary results in pre-clinical studies and clinical trials.
A novel inhibitor has been discovered that stalls a critical enzyme inside tumour cells, locking them in place and preventing invasion into healthy tissue. The findings hold promise for the development of metastasis-blocking agents.
A mutated gene in more than 20% of breast cancer recurrences promotes metastasis and resistance to hormone therapy. Researchers identify potential vulnerabilities, leading to the development of personalized treatment approaches.
Researchers at Weill Cornell Medicine discovered that cancer cells suppress a key enzyme in propionate metabolism, increasing production of methylmalonic acid (MMA) and causing cells to become more aggressive. This metabolic change may hold the key to understanding how tumors metastasize and developing novel therapies.
Researchers have found that treating prostate cancer cells with novel CDK8 and CDK19 inhibitors reduces their potential to migrate into surrounding structures. This suggests a promising approach to overcome resistance against anti-androgenic therapy, offering new therapeutic options for patients with advanced disease.
Researchers at CNIO have identified a biomarker for radioresistance in brain metastasis, which can help predict patient response to radiotherapy. They also found a drug that reverses radioresistance and demonstrated its potential in animal models and patient-derived cell cultures.
The AURORA study found that metastatic breast cancer tumors have distinct genetic and immune feature profiles compared to primary tumors. These differences may lead to more effective treatments by considering individual patient biopsies and biomarkers.
Researchers found that bacteria in tumors play a critical role in promoting cancer cell metastasis by modulating the cellular actin network and enhancing cell survival. This discovery could lead to new targets for preventing metastasis, potentially improving cancer treatment outcomes.
Researchers have identified a gene mutation in ARID2 that signals the development of aggressively metastatic melanoma. The study suggests patients with this mutation may require different treatment approaches to manage their cancer effectively. Further research is underway to refine this understanding and improve patient outcomes.
A study by MedUni Vienna reveals that mutations in the KMT2C protein lead to increased cell division, driving metastatic prostate cancer. This discovery may enable early diagnosis through a blood test and treatment with MYC inhibitors.
A research team at LKS Faculty of Medicine, The University of Hong Kong, has discovered a new molecular pathway governing melanoma angiogenesis and metastasis. They found that the expression of DEPDC1B is significantly associated with poor patient survival and positively correlated with melanoma growth and metastasis.
The American Association for Cancer Research (AACR) has announced the recipients of its 2022 Scientific Achievement Awards and Lectureships, recognizing Tony Hunter, Christina Curtis, John E. Dick, Kevan M. Shokat, and Lee M. Ellis for their groundbreaking contributions to cancer research.
A recent study from Memorial Sloan Kettering Cancer Center reveals that a specific genetic program, positional identity, determines the location of acral melanoma. The research, led by Dr. Richard White, found that this program is conserved throughout evolution and explains why certain mutations lead to cancer in specific areas. This b...
A new study from the University of Eastern Finland shows that liquid biopsy can detect cancer mutations months before recurrent breast cancer is detected. This method uses biomarkers released by cancer cells in serum samples to assess changes in intratumoural heterogeneity and provide a more accurate clinical picture.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
Researchers have identified two glucose transporters that disrupt the energy supply to invading worm cells and stop them in their tracks. By deactivating these genes, glucose and ATP levels dropped, and worm cells stalled their spread. This discovery could lead to new ways to cut off cancer cells' fuel lines and prevent metastasis.
Researchers Miao-Ping Chien and Daan Brinks have developed a method to detect aggressive cancer cells, which can help identify the genetic profile of individual cells and develop targeted medicines. This breakthrough has the potential to improve treatment outcomes for patients with cancer.
Researchers identify two genes, GLI1 and Notch1, responsible for aggressive growth and spread of triple negative breast cancers in African American women. A combination approach using inhibitors and chemotherapy agents significantly inhibits tumor growth and metastasis.
Researchers at Université catholique de Louvain have discovered a drug called MitoQ that prevents the appearance of metastases and local recurrences in human breast cancer. The molecule stops cancerous stem cells from awakening, offering a new treatment option for patients.
Melanoma skin cancer cells use Alzheimer's protein amyloid beta to survive in the brain, evading immune detection. A new study reveals a potential treatment target to counter this mechanism.
Researchers at UNIGE find that near-death experience in primary tumors triggers pro-metastatic states in cells, leading to metastasis. These 'PAME' cells reprogram themselves and trigger a cytokine storm, forming new tumors.
A study published in eLife reveals that cancer cells undergoing confined migration become more resistant to anoikis and exhibit increased invasiveness. This process may boost survival in cancer cells and make them more prone to forming deadly metastases.
Scientists have discovered a new therapeutic approach to aid the immune system in fighting cancer, offering hope for better solutions for patients. Researchers found that blocking the EP4 molecule can 'free' the immune system and restore its cancer-fighting functions.
Researchers have found that statins can inhibit the formation of tumors and metastases in animals with increased MACC1 expression. A study analyzing data from over 300,000 patients prescribed statins also showed a correlation between statin use and reduced cancer incidence.
Cedars-Sinai investigators discover that inhibiting RIPK2 function with drugs or CRISPR/Cas9 reduces prostate cancer metastasis in mice, offering new hope for advanced prostate cancer treatment. Targeting this protein could extend patients' lives by several years.
Researchers found that MYC inhibition by Omomyc exerts a dramatic effect on the metastatic process, reducing primary tumor and metastatic growth. The study suggests that MYC inhibition is anti-metastatic in breast cancer, offering promise as an anti-metastatic therapy.
Researchers have designed METPlatform, a drug screening platform compatible with patient biopsies, to investigate patients' own tumour tissue. The platform has identified new therapeutic targets and biomarkers for aggressive brain metastases, suggesting HSP90 inhibitors as potential treatments.
Researchers from National Cancer Centre Singapore have found a potential new strategy to treat peritoneal carcinomatosis, a metastatic form of intra-abdominal cancer. The team identified targeting ascites, excess fluid in the abdomen, as a way to remove fuel that drives cancer growth.
A new study highlights alternative treatment options that consider a patient's likelihood of recovery and quality of life. Total Definitive Treatment (TDT) is an approach that combines chemotherapy, radiation therapy, and close monitoring to potentially cure patients without surgery.
A study found that chemotherapy can trigger cancer metastasis by altering lung tissue and creating a supportive environment for cancer cells. The researchers discovered that the LOX enzyme's increased secretion by immune cells can lead to this phenomenon, which is relevant to other drugs and cancers.
Researchers have discovered that p53 protein activates a molecular program turning damaged cells into migratory leader cells for quick epithelial repair. Once repaired, these highly migratory cells are eliminated to restore normal epithelial tissue structure.
Scientists analyzed over 100,000 cells from 15 human brain metastases and identified two functional archetypes of metastatic cells, each containing both immune and non-immune cell types. These archetypes work together within single cells to shape inflammatory and proliferative processes co-existent in each metastatic tumor.
UCSF cancer biologist Hani Goodarzi is recognized for his groundbreaking research on cancer metastasis and novel molecular players. His work has led to the discovery of a protein driving breast cancer metastasis and orphan noncoding RNAs in cancerous cells.
Researchers at Children's Hospital of Philadelphia define a 3-tiered molecular classification system for pediatric differentiated thyroid cancer, where fusion oncogenes are associated with more invasive disease and lower remission rates. The study contrasts findings from adults, who have a two-tiered system based on BRAF mutations.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Melanoma cells release small packages containing the protein NGFR, which primes nearby lymph nodes to form new vessels and encourage cancer spread. This process, called lymphangiogenesis, may help doctors determine which patients need more aggressive treatment.
A new bilateral tumor model was demonstrated to be useful for investigating the relationship between T-cell repertoire and cancer immunotherapy's therapeutic effects. The study found that T-cell profiles of both tumors were almost identical, indicating a similar anti-tumor response in a single mouse.
A study investigated the common use of extended radiation therapy for patients with metastatic cancer nearing the end of life. Despite guidelines advising against this practice, researchers found that it is still used in many cases. The study aims to shed light on this treatment approach and its implications for patient care.
A study published in Cell Metabolism reveals unique features of brain metastasis in breast cancers, highlighting potential new targets for therapies. Researchers found that metabolically distinct cells have varying levels of glucose and glutamine usage, which can be targeted to reduce metastatic activity.
Researchers at Tufts University have found that manipulating voltage patterns in tumor cells can significantly reduce tumor cell invasion and metastasis in animal models. Using FDA-approved ion channel blockers, they were able to normalize cell voltages, decrease tumor growth, and limit the spread of cancer cells.
Researchers at Massachusetts General Hospital found that inhibiting the OR5B21 gene significantly decreased breast cancer metastasis to the brain, bones and lung. This discovery may lead to new therapeutic targets to prevent or delay breast cancer's spread.
Researchers have found that depleting copper levels in the body can greatly reduce the ability of cancer cells to metastasize, including aggressive breast cancer. The discovery provides hope for developing more effective treatments for high-risk triple-negative breast cancer.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
A recent UCLA-led study provided indirect evidence that PSMA PET/CT improves risk-stratification and prognostic capabilities for high-risk prostate cancer patients. The study found that PSMA nomogram outperformed existing tools in predicting clinical outcomes, suggesting its significance in disease course prediction.
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
The study used multigene sequencing to identify genomic alterations in patients with metastatic breast cancer. Patients with genomic alterations ranked as ESCAT I/II saw improved progression-free survival with targeted therapies matched to their genomic changes, while those without these alterations did not benefit from the treatment.
A study published in eLife reveals that a small signalling protein called ARL4C is overexpressed in pancreatic cancer patients, facilitating their aggressive behavior. By inhibiting ARL4C, researchers have shown promise in reducing the spread of pancreatic cancer cells, opening up new therapeutic avenues.